Back to Search
Start Over
Apalutamide-induced severe interstitial lung disease: A report of two cases from Japan
- Source :
- Respiratory Investigation. 59:700-705
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- Apalutamide, a competitive inhibitor of the androgen receptor, is being increasingly used for the treatment of prostate cancer. There have been few reports of interstitial lung disease in clinical trials of apalutamide. However, two cases of apalutamide-induced interstitial lung disease with respiratory failure in Japanese males, who were successfully treated with high-dose corticosteroids, are presented here. These cases suggest that clinicians should be alert to the potentially life-threatening risk of pulmonary toxicity associated with apalutamide treatment.
- Subjects :
- Male
Pulmonary and Respiratory Medicine
medicine.medical_specialty
Pulmonary toxicity
Antineoplastic Agents
Gastroenterology
03 medical and health sciences
Prostate cancer
chemistry.chemical_compound
0302 clinical medicine
Japan
Internal medicine
Humans
Medicine
030212 general & internal medicine
business.industry
Apalutamide
Interstitial lung disease
medicine.disease
Clinical trial
Androgen receptor
Prostatic Neoplasms, Castration-Resistant
Thiohydantoins
030228 respiratory system
Respiratory failure
chemistry
Methylprednisolone
Lung Diseases, Interstitial
business
medicine.drug
Subjects
Details
- ISSN :
- 22125345
- Volume :
- 59
- Database :
- OpenAIRE
- Journal :
- Respiratory Investigation
- Accession number :
- edsair.doi.dedup.....883b29059a9a8489c4b863c8f3424e8e